Table I.
Association of CPSF3 with clinicopathological features in The Cancer Genome Atlas lung adenocarcinoma patients.
| Variable | N | CPSF3 (mean ± SE) | t-value | P-value |
|---|---|---|---|---|
| Sex | ||||
| Female | 277 | 9.805±0.4380 | 1.804 | 0.0717 |
| Male | 237 | 9.876±0.4555 | ||
| Age, years | ||||
| <65 | 220 | 9.871±0.4691 | 1.693 | 0.0911 |
| ≥65 | 275 | 9.876±0.4252 | ||
| Smoking history | ||||
| Smoked | 75 | 9.700±0.4516 | 2.937 | 0.0035a |
| Never smoked | 425 | 9.766±0.3928 | ||
| Tumor diameter, cm | ||||
| ≤3 | 169 | 9.876±0.4677 | 2.638 | 0.0086a |
| >3 | 342 | 9.766±0.3928 | ||
| Lymph node metastasis | ||||
| No | 330 | 9.805±0.4598 | 2.763 | 0.0059a |
| Yes | 172 | 9.766±0.4188 | ||
| Distant metastasis | ||||
| M0 | 346 | 9.853±0.4440 | 1.611 | 0.1079 |
| M1 | 25 | 9.921±0.4796 | ||
| TNM stage | ||||
| I | 425 | 9.792±0.4115 | 4.178 | 0.0062a |
| II | 122 | 9.820±0.4917 | ||
| III | 84 | 9.961±0.4288b | ||
| IV | 25 | 9.979±0.4837b | ||
| Radiation therapy | ||||
| Yes | 60 | 9.812±0.4398 | 2.742 | 0.0063a |
| No | 397 | 9.981±0.4847 | ||
| Molecular therapy | ||||
| No | 303 | 9.804±0.4477 | 1.946 | 0.0523 |
| Yes | 152 | 9.891±0.4482 |
a
P<0.01
b
P<0.01 vs. stage I. Mean age, 65 years. TNM stage statistics were analyzed by one-way ANOVA and Bonferroni post hoc test. Other statistics were performed using a two-tailed Student's t-test. CPSF3, cleavage polyadenylation specific factor 3; TNM, tumor-node-metastasis.